



## **Annual Shareholders' Meeting 2023 of Siemens Healthineers AG**

### **Key Items of the Speech of Dr. Ralf P. Thomas, Chairman of the Supervisory Board**

#### ***Check against delivery.***

- Since we last met at our Annual Shareholders' Meeting a year ago, our world has changed in a way that would have hardly seemed possible: a war is raging in Europe. Hundreds of thousands are threatened by hunger and cold because they've been robbed of the basic foundations of modern civilization. We are experiencing one of the most severe energy crises in Europe since the Second World War. Rates of inflation are at a record high. Production and logistics chains are bogged down – due to the COVID-19 pandemic as well – posing enormous challenges for businesses.
- In this historically daunting environment, Siemens Healthineers has once again proven its mettle, and more. The company has responded in impressive fashion to the geopolitical upheaval: with record-breaking annual revenue of €21.7 billion and a new record profit for the year of €3.7 billion. The company twice raised its business outlook over the course of fiscal year 2022 – and achieved its targeted goals.
- The COVID-19 pandemic exacerbated the hardships inflicted by the war. Action moving forward will still demand prudence, diligence, and foresight. In this fiscal year just completed, we again managed to successfully maintain operations at our locations and ensure our delivery capability. The employees at our locations in Shanghai and Shenzhen demonstrated particularly impressive commitment to the company and society as a whole by voluntarily living on the company grounds for several weeks to keep MR and CT scanner production running while China was under pandemic lockdown.
- Equally impressive was the willingness that the company and its employees showed to help the people in Ukraine and those who fled their country, raising donations totaling some €2.7 million while also gifting medical imaging systems, laboratory equipment, and much more. These aid initiatives are a tangible expression of the spirit of our company purpose, translated directly into corporate social responsibility: "We pioneer breakthroughs in healthcare. For everyone. Everywhere."
- This newly defined corporate mission was formulated soon after closing the merger with Varian, marking the start of the third phase of implementing the Siemens Healthineers Strategy 2025. Dubbed "New Ambition", the goal of this phase is to firmly establish a higher and sustainably attractive level of growth and earnings for Siemens Healthineers by pursuing three strategic growth vectors. The growth vectors are: fighting the most threatening non-communicable diseases, enabling efficient operations in hospitals, and expanding access to modern medical care. Investments in research and development in fiscal year 2022 focused on these three growth vectors. All told, Siemens Healthineers

invested almost €1.8 billion in research and development. That's almost €240 million more than in the prior year.

- The company has continually worked toward achieving its environmental, social and governance objectives – what we call our "ESG goals". Siemens Healthineers has entered into effective partnerships to improve the quality of people's lives in under-served regions of the world, collaborating for example with UNICEF on a project in sub-Saharan Africa. In the area of environmental protection, we've introduced carbon-neutral operation as a global standard for all new company buildings. This bold aspiration applies in particular to the new facilities constructed at our locations in Forchheim, Germany as well as Bengaluru, India and Oxford, England. Last but not least, Siemens Healthineers today is one of three major companies on the DAX German stock index that have a balanced ratio of women to men on their Managing Board.
- When today's Annual Shareholders' Meeting closes, the mandate of four of my Supervisory Board colleagues will duly end. On behalf of the entire Supervisory Board, I wish to express my sincere gratitude to these four colleagues for their excellent, trusting cooperation and outstanding contributions in recent years to the well-being of Siemens Healthineers: Dr. Philipp Rösler, Dr. Gregory Sorensen, Dr. Norbert Gaus, and Dr. Andreas Hoffmann. The Supervisory Board proposes that my mandate be extended as well as the mandates of these Supervisory Board members: Dr. Marion Helmes, Dr. Nathalie von Siemens, and Karl-Heinz Streibich. The Supervisory Board proposes the appointment of the following new members of the Supervisory Board: Ms. Sarena Lin, Mr. Dow Wilson, Ms. Veronika Bienert, and Dr. Peter Körte. We firmly believe that this lineup of proposed candidates will put the Supervisory Board in an ideal position to continue successfully supporting Siemens Healthineers AG moving forward, and live up to the body's governance duties.
- The Supervisory Board fulfilled its duties in fiscal year 2022 in accordance with the law and the company's Articles of Association and Rules of Procedure. It held seven regular meetings and adopted two resolutions in writing. The object of our regular consultations in plenary session were the company's financial position and financial performance, including the impacts of the COVID-19 pandemic as well as the employment trend at Siemens Healthineers. The detailed Report of the Supervisory Board can be found starting on page 113 of the 2022 Annual Report.